1. Home
  2. BQ vs PRFX Comparison

BQ vs PRFX Comparison

Compare BQ & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.93

Market Cap

3.2M

ML Signal

HOLD

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$1.60

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
PRFX
Founded
2008
2007
Country
China
Israel
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
2.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
BQ
PRFX
Price
$0.93
$1.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
4.4M
Earning Date
01-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.58
52 Week High
$72.74
$5.39

Technical Indicators

Market Signals
Indicator
BQ
PRFX
Relative Strength Index (RSI) 50.68 47.68
Support Level $0.69 $1.29
Resistance Level $0.96 $2.89
Average True Range (ATR) 0.17 0.41
MACD 0.01 0.02
Stochastic Oscillator 30.81 11.11

Price Performance

Historical Comparison
BQ
PRFX

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

Share on Social Networks: